Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and Pfizer Inc. (NYSE: PFE) today reported further positive Phase 2 data for their Lyme disease vaccine candidate, VLA15. Based on these new results, Valneva and Pfizer plan to proceed with a three-dose primary series vaccination schedule in a planned Phase 3 clinical trial.
Valneva and Pfizer report further positive Phase 2 data for Lyme disease vaccine candidate
February 4, 2022
Related blog posts
New drug shows promise for fighting both COVID-19 and cancer
November 15, 2022